Stroke
April 2015 Clinical outcomes with endovascular therapy are potentially influenced by hospital size, work-flow processes, availability of stroke units, rapid access to care, optimal poststroke therapy and patient demographics. [16] [17] [18] [19] In this study, we used data from the Get With The Guidelines (GWTG)-Stroke registry to determine secular trends in endovascular therapy use and hospital discharge outcomes during the past decade. We also analyze hospital and patient-level characteristics associated with the use of this therapy and resultant clinical outcomes.
Methods
GWTG-Stroke is a voluntary quality improvement initiative whose details have been described previously. 20, 21 We analyzed data submitted to GWTG-Stroke during the time period April 1, 2003 , to June 30, 2013 . The study population, hospital-, and patient-level variables analyzed are described in the online-only Data Supplement. The use of endovascular therapy for acute ischemic stroke was recorded but not the type of therapy (eg, whether intra-arterial fibrinolysis, mechanical clot retrieval, angioplasty, stenting, alone or in combination). Clinical outcomes studied included symptomatic intracerebral hemorrhage (sICH), in-hospital mortality, length of hospital stay, and ambulatory status at discharge.
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Statistical Analysis
Data were summarized using standard descriptive statistics. Trends over time in the number of hospitals providing endovascular therapy and in the use of endovascular therapy in these hospitals were reported as proportions. Hospital-level characteristics were compared between hospitals providing endovascular therapy and those not. Multivariable logistic regression was used to identify hospital-level variables that are independently associated with hospitals that provide endovascular therapy. Hospitals with bed size or teaching status missing (n=10) were excluded from this analysis.
Patient-level characteristics were compared between patients receiving endovascular therapy and those not as above. Using multivariable logistic regression and a generalized estimating equations approach with exchangeable working correlation matrix that takes into account within hospital clustering of patient-level data, patientlevel variables associated with the use of endovascular therapy were identified. Missing data on most variables were <5%, except for arrival mode, the use of antihypertensives and the use of antidiabetic medications before admission (10% missing). A simple imputation to dominant level was used for these variables. Whenever data were missing on hospital variables, these were excluded from analysis. Because vital signs, laboratory data, anticoagulation, and antiplatelet use before admission had >45% missing, these variables were excluded from analysis. In patients receiving endovascular therapy, time from stroke symptom onset to hospital arrival was included in the multivariable analysis identifying patient-and hospital-level variables associated with various clinical outcomes. The primary multivariable analysis was restricted to patients with baseline National Institutes of Health Stroke Scale (NIHSS) data available. A sensitivity analysis that did not include NIHSS in the model was also done.
Finally, we analyzed trends over time for prespecified clinical outcomes in patients receiving endovascular therapy. Unadjusted data showed a significant improvement in many clinical outcomes from the fourth quarter of 2010 (31st quarter of total time interval from April 1, 2003 , to June 30, 2013 . To identify patient-and hospitallevel variables associated with the prespecified clinical outcomes and to identify risk adjusted trends over time in these outcomes in patients receiving endovascular therapy, we used multivariable logistic regression and the generalized estimating equations approach as above; calendar time was evaluated for nonlinearity in the association with the binary outcomes by fitting a restricted cubic spline. The spline fit is plotted for predicted outcomes by calendar time from April 2003 to June 2013 with confidence bounds using the mean of covariates for all other covariates; for mortality and LOS (log transformed), a single linear relationship is assessed (P=0.45 for nonlinearity test for mortality and 0.74 for LOS). For other outcomes, data and plot suggested calendar time included in these models as a continuous variable using 2 pieces of splines with a single cut point at the 31st quarter. All P values are 2 sided, with P<0.05 considered statistically significant. Analyses were performed using SAS software (version 9.2; SAS Institute, Cary, NC).
Results
Of 1087 hospitals, 454 (41.8%) provided endovascular therapy to ≥1 patient during the study period. After excluding 28 hospitals without full calendar year data, 99 of 1059 (9.4%) hospitals provided continuous endovascular therapy. In hospitals providing any endovascular therapy, 9506 (1.6%) of patients with ischemic stroke received endovascular therapy, including 6296 (1.1%) patients receiving endovascular therapy alone and 3210 (0.5%) receiving both endovascular therapy and intravenous tissue-type plasminogen activator (tPA). By comparison, 47 333 of 592 414 (8.0%) of patients with ischemic stroke in these hospitals received intravenous tPA alone without endovascular therapy. At hospitals continuously providing endovascular therapy (n=99), the median annual number of patients receiving endovascular therapy was 6 (interquartile range, 3.6-10), whereas the median percentage of patients with acute ischemic stroke receiving endovascular therapy was 2.6% (interquartile range, 1.6%-4.4%).
An increase over time in the proportion of hospitals providing endovascular therapy was noted from 2003 to 2012, increasing at 1.6% per year (P<0.0001), with a modest drop in 2013 after the reporting of neutral randomized trials ( Figure 1) . Similarly, the proportion of patients treated with endovascular therapy at hospitals providing this therapy increased from 0.7% to 2% from 2003 to 2012 (P<0.001), with a modest drop in 2013.
Hospital-level characteristics associated with endovascular therapy are shown Table I in the online-only Data Supplement (univariate analysis) and Table 1 (multivariable  analysis, adjusted for NIHSS) . On multivariable analysis, at hospital level, larger teaching hospitals in urban areas treating more patients with ischemic stroke per year and with higher annual intravenous tPA administration rates were more likely to administer endovascular therapy. No geographic or raceethnic patient mix differences in the likelihood of hospitals offering endovascular therapy were noted. Hospitals that treat more women were less likely to offer endovascular therapy. In analysis of characteristics associated with hospitals offering endovascular therapy continuously, independent associations were with higher annual ischemic stroke rate, higher annual intravenous tPA administration rate, and higher proportion of non-Hispanic white patients.
Patient-level characteristics associated with endovascular therapy are shown in Table I in the online-only Data Supplement (univariate analysis) and Table 1 (multivariable analysis, adjusted for NIHSS). On multivariable analysis, patients who were offered endovascular therapy were more likely to be younger and not have a history of previous stroke/ transient ischemic attack. Patients arriving during on-hours were more likely to receive endovascular therapy than those arriving during off-hours. Patients transported by Emergency Medical Services (EMS) were also more likely to receive endovascular therapy. Other patient-level variables associated with the use of endovascular therapy include history of atrial fibrillation, having a prosthetic heart valve, history of coronary artery disease/myocardial infarction, history of carotid stenosis, absence of history of diabetes mellitus, peripheral vascular disease, hypertension, and smoker, use of statins, no use of diabetic medications before admission and nonfemale and nonblack ethnicity. In sensitivity analyses for all patients, the model remained the same with the following exceptions; male sex, history of carotid stenosis, and absence of history of peripheral vascular disease were not associated with the use of endovascular therapy, whereas history of heart failure was, and the magnitude of association with EMS arrival was increased.
Clinical outcomes in patients receiving endovascular therapy are described in Table 2 . Functional and safety outcomes did not differ among patients receiving combined intravenous tPA and endovascular therapy and patients receiving endovascular therapy alone. Variables associated with in-hospital mortality among patients offered endovascular therapy are shown in Table II in the online-only Data Supplement and included older age, history of coronary artery disease or previous myocardial infarction, history of diabetes mellitus, history of heart failure, EMS arrival, and no statin before admission. Mortality was also lower in hospitals that offered more endovascular therapy but higher in hospitals that offered more intravenous tPA therapy. Mortality was lower in the Midwest compared with that in the Northeast. Variables associated with discharge home among patients offered endovascular therapy are shown in Table II in the online-only Data Supplement and included younger age, male sex, nonblack race, absence of history of diabetes mellitus and hypertension, arriving during work hours rather than during off-hours and not brought to hospital by EMS. Discharge home was more likely in hospitals that offered more endovascular therapy. Variables associated with patients who ambulate independently at discharge and those associated with longer length of stay in hospital among patients offered endovascular therapy are described in Table II in the online-only Data Supplement. Adding NIHSS at baseline into the models resulted in that variable being a significant predictor of all outcomes. The association of on-hours versus off-hours admission on discharge home, ambulatory status, and mortality reduced significantly when adjusted for baseline NIHSS (Table III in 
Discussion
We analyzed trends in the use and outcomes of endovascular therapy from 2003 to 2013 using data from 977 885 patients with acute ischemic stroke and 1087 hospitals participating in a large US-based registry. We find that 2 of every 5 participating hospitals have provided endovascular therapy in the past decade; however, only 1 of every 10 hospitals provided endovascular therapy in every participating year. Among hospitals that provide continuous endovascular therapy, only 25% treat ≥10 patients per year. We also note increasing use of endovascular therapy from 2003 to 2012 with a mild decrement in 2013, after neutral trials of first-generation interventions were published.
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The overall rate of sICH in patients receiving endovascular therapy was 9.7%, whereas overall in-hospital mortality rate was 19.4%. We also found that every second patient stayed in hospital for at least a week, 1 of every 5 patients was discharged home, 1 of every 4 patients was able to ambulate independently, whereas 2 of every 3 patients were able to ambulate with assistance. These clinical outcome rates are similar to those reported for acute ischemic stroke endovascular therapy patients in US Nationwide Inpatient Sample data for the years 2004 to 2009.
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Our results also show substantial reduction in adverse outcomes over time. The rate of sICH in patients receiving endovascular therapy declined from 1 in 7 to 1 in 20 over the study period. The risk-adjusted rate of in-hospital mortality declined from 1 in 3 to 1 in 7. The sICH and in-hospital mortality rates in the final 2 years of the observation period (2012-2013) are 3 absolute percentage points lower than those reported in the endovascular arm of the Interventional Management of Stroke III trial. 10 This decline in mortality was accompanied in the latter study years (2010) (2011) (2012) (2013) by an increase in the proportion of patients being discharged home after endovascular therapy, suggesting that increasing survival did not come at the cost of increasing disability. This time period coincides with increasing use of new mechanical devices like the Penumbra aspiration system (Food and Drug Administration cleared in 2008) and stentrievers (Food and Drug Administration cleared in 2012) for endovascular therapy. These mechanical devices have higher recanalization rates than previous generation devices, achieve recanalization faster, and have lower complication rates. 6, 13, 14 Our results raise the possibility that increasing use of newer mechanical devices has resulted in better clinical outcome although other changes in practice such as better patient selection, more technical expertise, better periprocedural care, and improved healthcare systems may also explain some or all of the improvement in clinical outcomes in recent years. [7] [8] [9] We are unable to analyze outcomes according to recanalization method or devices directly because the device type is not captured in the GWTG data set. Of note, however, our analysis was risk adjusted, thus correcting for any baseline differences in stroke severity of patients treated over time.
Endovascular therapy was provided inconsistently and to only a small minority of patients (1.6%) in the hospitals included in this study. Even among hospitals that consistently provided endovascular therapy, only a median of 2.6% patients was treated. More patients received endovascular therapy alone (1.1%) than combined intravenous tPA and endovascular therapy (0.5%). A potential reason for higher use of endovascular therapy alone versus combined therapy could be physician preference to offer this therapy to patients with disabling stroke whenever intravenous tPA is contraindicated. In addition, patients from remote areas reaching a comprehensive stroke center beyond time window for intravenous tPA administration may also be offered endovascular therapy alone. Nonetheless, the observation that the proportion of patients given endovascular therapy is still increasing, with disparities by geographic location, age, sex and race, suggests that endovascular therapy is still incompletely adopted in ischemic stroke practice. Our findings contrast with a study of endovascular therapy using data from the Nationwide Inpatient Sample that showed even lower adoption of acute ischemic stroke endovascular therapy (0.1% in 2004 to 0.6% 
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April 2015 in 2009). 22 Higher adoption rates in hospitals in our study could be because these hospitals have committed to quality improvement in stroke care through the GWTG-Stroke program. These hospitals, therefore, may not be representative of all US hospitals.
We find that larger teaching hospitals in urban areas use endovascular therapy more than smaller, nonteaching hospitals in rural areas. We also find that hospitals using more endovascular therapy show better clinical outcomes and lower mortality rates than hospitals that use this therapy infrequently. These hospitals may be larger, more organized, and have more trained personnel operating 24/7 hours. There is increasing evidence that organized, dedicated, high-volume stroke centers improve patient outcomes. 23, 24 A centralized model of endovascular care with a high-volume dedicated hub hospital receiving patients could help in maintaining case volumes, expertise and efficient in-hospital systems, reducing door to recanalization times, thereby further improving patient outcomes.
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Patients arriving at endovascular hospitals during offhours were less likely to be offered this therapy; in addition, patients offered endovascular therapy during off-hours were less likely to be discharged home or ambulate independently. This association of off-hour admission weakens when analysis is adjusted for baseline NIHSS. An association of offhour admission with poorer outcomes has been demonstrated before in patients with strokes albeit not with endovascular therapy; many observers think that this effect to be because of differences in quality of care and delay in administering therapy.
26,27 Considerable weakening of this association in our study when adjusting for baseline stroke severity suggests that patients presenting during off-hours may have more severe strokes, a diurnal pattern well described in patients with myocardial infarction.
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Our study found differences in the use of endovascular therapy based on age, sex, and race/ethnicity. Older patients, women, and nonwhite patients were less likely to be offered this therapy; interestingly, if offered this therapy, these same patients were less likely to do well clinically. Data on insurance were only collected since 2008; hence, we did not analyze differences in the use of endovascular therapy because of availability of insurance. Our results support previous literature on this topic. 29 Age, sex, and race-ethnic differences could be because of differences in access, in education and awareness, and also to differences in stroke pathophysiology.
Our study has limitations. Patients and hospitals may not be entirely representative of the US population. Nonetheless, the demographics of the GWTG-Stroke patient population are similar to the overall demographics of all US patients with stroke. 30 We had data on stroke onset to hospital arrival time but did not have details on other interval times within the endovascular workflow, or what drugs or devices were used. We also did not have data on the modified Rankin Scale as an outcome measure. Nonetheless, we report on measures of functional independence like ambulatory status and mortality that have correlated well with the modified Rankin Scale.
In summary, we note limited use of endovascular therapy for patients with acute ischemic stroke in hospitals capable of offering this therapy. Our results also show that the use increased, albeit mildly, from 2003 to 2012 and then most recently mildly declined with the presentation of 3 neutral randomized clinical trials of early generation technology.
7-9 Our data also suggest more recent improvement in clinical outcomes in patients receiving endovascular therapy, coincident with the introduction and dissemination of later generation mechanical devices, and possibly associated with increased expertise among physicians and hospital systems in taking care of these patients. Results of recent randomized trials of these new devices will, however, be critical in providing the evidence needed to justify reorganizing and further improving stroke systems of care.
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SUPPLEMENTAL MATERIAL
Methods
Study Population: We analyzed data submitted to GWTG-Stroke during the time period April 1, 2003 to June 30, 2013 . After excluding hospitals with <75% complete data, there were 1,521,253 consecutive patients with acute ischemic stroke from 1,926 hospitals. From this cohort, we excluded hospitals with < 4 quarters (1 year) of data submitted or with < 100 ischemic stroke admissions, leaving 1,125,596 patients from 1,087 hospitals. After excluding patients with missing discharge destination (n=12,930), patients transferred in from another hospital and therefore lacking admission and treatment details from that hospital (n=134,598) and patients who received endovascular therapy at a different hospital prior to arrival (n=183), the final study population consisted of 977,885 patients from 1,087 hospitals. Hospitals providing endovascular therapy were defined as hospitals that provided this therapy to at least one patient during their participating years within the study period. In addition, we did sensitivity analyses of hospitals that provide continuous endovascular therapy, defined as treating at least one patient each full participating year during the study period. We studied patient level characteristics associated with utilization of endovascular therapy only in those hospitals that provide endovascular therapy. For this analysis, there were 601,920 patients from 454 hospitals. Finally, when studying hospital and patient level characteristics associated with clinical outcome in patients receiving endovascular therapy, we excluded patients transferred out to a different acute care hospital (n=7,052), those not receiving endovascular therapy (n=585,541), those with missing last known well time (n=1,002), those with hospital arrival time missing (n=330) and those presenting > 8 hours from stroke symptom onset (n=970). This final analysis therefore included 7,025 patients treated with endovascular therapy from 416 hospitals. IQR; inter-quartile range, IV; intravenous; tPA; tissue plasminogen activator, NIH; National Institute of Health, EMS; emergency medical services, sICH; symptomatic intracranial hemorrhage; PMHX, past medical history; EMS, emergency medical services; PSC, Joint Commission-certified primary stroke center. 
